164 related articles for article (PubMed ID: 38429845)
1. Single-cell deconvolution algorithms analysis unveils autocrine IL11-mediated resistance to docetaxel in prostate cancer via activation of the JAK1/STAT4 pathway.
Cheng B; Li L; Luo T; Wang Q; Luo Y; Bai S; Li K; Lai Y; Huang H
J Exp Clin Cancer Res; 2024 Mar; 43(1):67. PubMed ID: 38429845
[TBL] [Abstract][Full Text] [Related]
2. Autocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cells.
Onnis B; Fer N; Rapisarda A; Perez VS; Melillo G
J Clin Invest; 2013 Apr; 123(4):1615-29. PubMed ID: 23549086
[TBL] [Abstract][Full Text] [Related]
3. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells.
Nalairndran G; Chung I; Abdul Razack AH; Chung FF; Hii LW; Lim WM; Looi CK; Mai CW; Leong CO
J Cell Mol Med; 2021 Sep; 25(17):8187-8200. PubMed ID: 34322995
[TBL] [Abstract][Full Text] [Related]
5. Single-Cell Transcriptomics Analysis Identifies Nuclear Protein 1 as a Regulator of Docetaxel Resistance in Prostate Cancer Cells.
Schnepp PM; Shelley G; Dai J; Wakim N; Jiang H; Mizokami A; Keller ET
Mol Cancer Res; 2020 Sep; 18(9):1290-1301. PubMed ID: 32513898
[TBL] [Abstract][Full Text] [Related]
6. The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.
Lundon DJ; Boland A; Prencipe M; Hurley G; O'Neill A; Kay E; Aherne ST; Doolan P; Madden SF; Clynes M; Morrissey C; Fitzpatrick JM; Watson RW
BMC Cancer; 2017 Mar; 17(1):163. PubMed ID: 28249598
[TBL] [Abstract][Full Text] [Related]
7. NOTCH3 promotes docetaxel resistance of prostate cancer cells through regulating TUBB3 and MAPK signaling pathway.
Sun X; Zhang Y; Xin S; Jin L; Cao Q; Wang H; Wang K; Liu X; Tang C; Li W; Li Z; Wen X; Yang G; Guo C; Liu Z; Ye L
Cancer Sci; 2024 Feb; 115(2):412-426. PubMed ID: 38115797
[TBL] [Abstract][Full Text] [Related]
8. Co-transcriptional R-loops-mediated epigenetic regulation drives growth retardation and docetaxel chemosensitivity enhancement in advanced prostate cancer.
Ying Y; Wu Y; Zhang F; Tang Y; Yi J; Ma X; Li J; Chen D; Wang X; Liu X; Liu B; Luo J; Zheng X; Xie L
Mol Cancer; 2024 Apr; 23(1):79. PubMed ID: 38658974
[TBL] [Abstract][Full Text] [Related]
9. Residual prostate cancer cells after docetaxel therapy increase the tumorigenic potential via constitutive signaling of CXCR4, ERK1/2 and c-Myc.
Hatano K; Yamaguchi S; Nimura K; Murakami K; Nagahara A; Fujita K; Uemura M; Nakai Y; Tsuchiya M; Nakayama M; Nonomura N; Kaneda Y
Mol Cancer Res; 2013 Sep; 11(9):1088-100. PubMed ID: 23788635
[TBL] [Abstract][Full Text] [Related]
10. The
Hagberg N; Joelsson M; Leonard D; Reid S; Eloranta ML; Mo J; Nilsson MK; Syvänen AC; Bryceson YT; Rönnblom L
Ann Rheum Dis; 2018 Jul; 77(7):1070-1077. PubMed ID: 29475858
[TBL] [Abstract][Full Text] [Related]
11. Autocrine Loop Involving IL-6 Family Member LIF, LIF Receptor, and STAT4 Drives Sustained Fibroblast Production of Inflammatory Mediators.
Nguyen HN; Noss EH; Mizoguchi F; Huppertz C; Wei KS; Watts GFM; Brenner MB
Immunity; 2017 Feb; 46(2):220-232. PubMed ID: 28228280
[TBL] [Abstract][Full Text] [Related]
12. Co-operative functions between nuclear factors NFkappaB and CCAT/enhancer-binding protein-beta (C/EBP-beta) regulate the IL-6 promoter in autocrine human prostate cancer cells.
Xiao W; Hodge DR; Wang L; Yang X; Zhang X; Farrar WL
Prostate; 2004 Dec; 61(4):354-70. PubMed ID: 15389813
[TBL] [Abstract][Full Text] [Related]
13. MEK/ERK/RUNX2 Pathway-Mediated IL-11 Autocrine Promotes the Activation of Müller Glial Cells during Diabetic Retinopathy.
Ji N; Guo Y; Liu S; Zhu M; Tu Y; Du J; Wang X; Wang Y; Song E
Curr Eye Res; 2022 Dec; 47(12):1622-1630. PubMed ID: 36154781
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.
Gu L; Talati P; Vogiatzi P; Romero-Weaver AL; Abdulghani J; Liao Z; Leiby B; Hoang DT; Mirtti T; Alanen K; Zinda M; Huszar D; Nevalainen MT
Mol Cancer Ther; 2014 May; 13(5):1246-58. PubMed ID: 24577942
[TBL] [Abstract][Full Text] [Related]
15. TGF-β causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization.
Li Y; Zhang B; Xiang L; Xia S; Kucuk O; Deng X; Boise LH; Dong JT
Theranostics; 2020; 10(17):7656-7670. PubMed ID: 32685011
[TBL] [Abstract][Full Text] [Related]
16. JAK pathway induction of c-Myc critical to IL-5 stimulation of cell proliferation and inhibition of apoptosis.
Lee WH; Liu FH; Lin JY; Huang SY; Lin H; Liao WJ; Huang HM
J Cell Biochem; 2009 Apr; 106(5):929-36. PubMed ID: 19180571
[TBL] [Abstract][Full Text] [Related]
17. Use of miR‑145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer.
Zhu J; Qin P; Cao C; Dai G; Xu L; Yang D
Oncol Rep; 2021 Mar; 45(3):963-974. PubMed ID: 33650661
[TBL] [Abstract][Full Text] [Related]
18. Circ_0004087 interaction with SND1 promotes docetaxel resistance in prostate cancer by boosting the mitosis error correction mechanism.
Chen L; Song Y; Hou T; Li X; Cheng L; Li Y; Xing Y
J Exp Clin Cancer Res; 2022 Jun; 41(1):194. PubMed ID: 35659274
[TBL] [Abstract][Full Text] [Related]
19. Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers.
Hornakova T; Staerk J; Royer Y; Flex E; Tartaglia M; Constantinescu SN; Knoops L; Renauld JC
J Biol Chem; 2009 Mar; 284(11):6773-81. PubMed ID: 19139102
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells.
Liu C; Zhu Y; Lou W; Cui Y; Evans CP; Gao AC
Prostate; 2014 Feb; 74(2):201-9. PubMed ID: 24307657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
